


## Validation of advanced treatment for rheumatoid arthritis (toIDC)

### Participant Flow



### Baseline Characteristics

Table 1. Demographic characteristics of patients screened

Demographic characteristics	Group (n=13)
Sex (female), n (%)	8 (62%)
Ethnicity (white), n (%)	13 (100%)
Age (50-59), n (%)	2 (15%)
(60-69), n (%)	6 (46%)
(70-79), n (%)	4 (31%)
(80-89), n (%)	1 (8%)

### Outcome Measures

Table 2. Summary of study objectives and their outcomes

	<u>Objectives</u>	<u>Outcome Measures</u>
<b>Primary</b>	Number of patients successfully completing leukapheresis procedure	7 successful leukapheresis procedures occurred obtaining product suitable for the manufacture of toIDC
<b>Secondary</b>	To manufacture, from RA patient leukocytes, toIDC that meet GMP validation criteria in the Newcastle Cellular Therapies Facility.	Validation runs were successfully completed to allow development of an IMPD for use in the AuToDeCRA-2 clinical trial.

### Adverse Events

Table 1. Incidence of adverse events

Adverse Event	Incidence
Lightheaded / headache	1